Linking LOXL2 to cardiac interstitial fibrosis

Simple item page
dc.contributor.authorErasmus, M.
dc.contributor.authorSamodien, E.
dc.contributor.authorLecour, S.
dc.contributor.authorCour, M.
dc.contributor.authorLorenzo, O.
dc.contributor.authorDludla, P.
dc.contributor.authorPheiffer, C.
dc.contributor.authorJohnson, R.
dc.contributor.departmentBiomedical Research and Innovation Platform, South African Medical Research Councilen_US
dc.date.accessioned2023-04-17T12:26:48Z
dc.date.available2023-04-17T12:26:48Z
dc.date.epub2020
dc.date.issued2020-08-18
dc.description.abstractCardiovascular diseases (CVDs) are the leading causes of death worldwide. CVD pathophysiology is often characterized by increased stiffening of the heart muscle due to fibrosis, thus resulting in diminished cardiac function. Fibrosis can be caused by increased oxidative stress and inflammation, which is strongly linked to lifestyle and environmental factors such as diet, smoking, hyperglycemia, and hypertension. These factors can affect gene expression through epigenetic modifications. Lysyl oxidase like 2 (LOXL2) is responsible for collagen and elastin cross-linking in the heart, and its dysregulation has been pathologically associated with increased fibrosis. Additionally, studies have shown that, LOXL2 expression can be regulated by DNA methylation and histone modification. However, there is a paucity of data on LOXL2 regulation and its role in CVD. As such, this review aims to gain insight into the mechanisms by which LOXL2 is regulated in physiological conditions, as well as determine the downstream effectors responsible for CVD development.en_US
dc.description.sponsorshipFunding: The work reported herein was made possible through funding by the South Africa Medical Research Council’sBiomedicalResearchandInnovationPlatformbaselinefundingaswellasDivisionofResearchCapacity DevelopmentInternshipScholarshipandIntra-muralPost-DoctoralScholarshipProgram. As well as the National Research Foundation (NRF)ThuthukaProgramme107261,theCompetitiveprogramforRatedResearchers(CPRR) 120812,theNRF,ProfessionalDevelopmentProgramme(PDP)grant104912,NRFgrant117829,theNRFExtension grant12098,andtheSouthAfricanRooibosCouncilgrant. In addition, The NRF echocardiograph large equipment Grant at the University of Cape Town.en_US
dc.identifier.citationErasmus M, Samodien E, Lecour S, Cour M, et al. Linking LOXL2 to Cardiac Interstitial Fibrosis. Int J Mol Sci. 2020 Aug 18;21(16):5913.doi:10.3390/ijms21165913.en_US
dc.identifier.doi10.3390/ijms21165913
dc.identifier.journalInternational Journal of Molecular Sciencesen_US
dc.identifier.urihttps://www.mdpi.com/1422-0067/21/16/5913
dc.identifier.urihttps://infospace.mrc.ac.za/handle/11288/595296
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.research.unitBiomedical Research and Innovation Platformen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subjectDNA methylationen_US
dc.subjectLysyl Oxidase-Like 2 (LOXL2)en_US
dc.subjectCardiovascular disease (CVD)en_US
dc.subjectEpigeneticsen_US
dc.subjectFibrosisen_US
dc.titleLinking LOXL2 to cardiac interstitial fibrosisen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Erasmus M_2020_Linking.pdf
Size:
2.6 MB
Format:
Adobe Portable Document Format
Description:
Thumbnail Image
Name: Erasmus M_2020_Linking.pdf
Size: 2.6 MB
Kind: Adobe PDF
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Name: license.txt
Size: 1.71 KB
Kind: License
Collections
Intramural: Journal Articles